Search results for "Triglyceride"

showing 10 items of 444 documents

A Genome-Wide Screen for Interactions Reveals a New Locus on 4p15 Modifying the Effect of Waist-to-Hip Ratio on Total Cholesterol

2011

Recent genome-wide association (GWA) studies described 95 loci controlling serum lipid levels. These common variants explain ∼25% of the heritability of the phenotypes. To date, no unbiased screen for gene–environment interactions for circulating lipids has been reported. We screened for variants that modify the relationship between known epidemiological risk factors and circulating lipid levels in a meta-analysis of genome-wide association (GWA) data from 18 population-based cohorts with European ancestry (maximum N = 32,225). We collected 8 further cohorts (N = 17,102) for replication, and rs6448771 on 4p15 demonstrated genome-wide significant interaction with waist-to-hip-ratio (WHR) on …

Netherlands Twin Register (NTR)Adipose Tissue/metabolismAdipose Tissue/metabolism; Body Fat Distribution; Cadherins/genetics; Cholesterol/blood; Cholesterol/genetics; Chromosome Mapping; Chromosomes Human Pair 4/genetics; European Continental Ancestry Group/genetics; Genome-Wide Association Study; Genotype; Humans; Lipids/blood; Lipids/genetics; Lipoproteins/blood; Lipoproteins/genetics; Phenotype; Polymorphism Single Nucleotide; Quantitative Trait Loci/genetics; Risk Factors; Triglycerides/blood; Triglycerides/genetics; Waist-Hip RatioGenome-wide association study0302 clinical medicineGenetics(clinical)AetiologyEuropean Continental Ancestry Group/genetics0303 health scienceseducation.field_of_studyta3141ta3142ASSOCIATIONCadherinsLipids3. Good healthTriglycerides/bloodCholesterolAdipose TissueDENSITY-LIPOPROTEIN CHOLESTEROLTRIGLYCERIDEChromosomes Human Pair 4SMOKING/dk/atira/pure/subjectarea/asjc/1100/1105Human/dk/atira/pure/subjectarea/asjc/1300/1311/dk/atira/pure/subjectarea/asjc/1300/1312GenotypeLipoproteinseducationEuropean Continental Ancestry GroupQuantitative Trait LociLocus (genetics)Cholesterol/bloodWhite People03 medical and health sciencesSDG 3 - Good Health and Well-beingClinical ResearchGenome-Wide Association StudiesGeneticsHumansPolymorphismeducationBiologyMolecular BiologyPOLYMORPHISMSEcology Evolution Behavior and Systematics0604 GeneticsHDL CHOLESTEROLScience & TechnologyCadherins/geneticsChromosomes Human Pair 4/geneticsQuantitative Trait Loci/geneticsDensity-lipoprotein cholesterol; HDL chloesterol; Association; Gene; Smoking; Plasma; Triglyeride; Obesity; Lipids; PolymorphismsDevelopmental BiologyCancer Research030204 cardiovascular system & hematologyWaist–hip ratioRisk FactorsGenotype2.1 Biological and endogenous factorsBody Fat DistributionGENETICS & HEREDITYGenetics (clinical)GeneticsPLASMAChromosome MappingSingle NucleotideENGAGE ConsortiumPair 4/geneticsPhenotypePair 4OBESITY/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being/dk/atira/pure/subjectarea/asjc/1300/1306Life Sciences & BiomedicineResearch ArticleLIPIDSlcsh:QH426-470PopulationQuantitative trait locusBiologyPolymorphism Single NucleotideChromosomes/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_Lipoproteins/bloodgene ; waist-to-hip ratio ; cholesterolAlleleTriglycerides030304 developmental biologyWhitesLipids/bloodWaist-Hip RatioHuman GenomeHuman Genetics/dk/atira/pure/subjectarea/asjc/2700/2716HeritabilityGENEProtocadherinslcsh:Genetics3111 BiomedicineGenome-Wide Association StudyPLoS Genetics
researchProduct

Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells

2015

Here, the potential of two nanostructured lipid carriers (NLC) for controlled release of sorafenib was evaluated. The obtained systems showed characteristics suitable as drug delivery systems for the treatment of hepatocellular carcinoma (HCC) through parenteral administration. The use of a mixture between a solid lipid (tripalmitin) with a liquid lipid (Captex 355 EP/NF or Miglyol 812) to prepare NLC systems could give a higher drug loading capacity and a longer term stability during storage than that obtained by using only solid lipids. The obtained nanoparticles showed a nanometer size and high negative zeta potential values. Scansion electron microscopy (SEM) of the sorafenib loaded NLC…

NiacinamideSorafenibDrugCell Survivalmedia_common.quotation_subjectnanostructured lipid carriersPharmaceutical ScienceAntineoplastic AgentsPharmacologyHemolysischemistry.chemical_compoundNanostructured lipid carriers Sorafenib Drug release Angiogenesis inhibitor HepatocarcinomamedicineZeta potentialHumansParticle SizeChromatography High Pressure LiquidTriglyceridesdrug releasemedia_commonDrug CarriersPhenylurea CompoundsHep G2 Cellsmedicine.diseaseLipidsControlled releasedigestive system diseasesIn vitroDrug Liberationangiogenesis inhibitorchemistryhepatocarcinomaSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDelayed-Action PreparationsHepatocellular carcinomaTripalmitinDrug deliveryMicroscopy Electron ScanningNanoparticlessorafenibCaprylatesmedicine.drug
researchProduct

Medium-chain triglycerides may improve memory in non-demented older adults: a systematic review of randomized controlled trials

2022

Abstract Background Ketosis has been exploited for its neuroprotective impact and treatment of neurological conditions via ketone production. Exogenous medium-chain triglyceride (MCT) supplementation may induce nutritional ketosis. The aim of this systematic review is to explore the effects of MCTs on memory function in older adults without cognitive impairment. Methods A systematic literature search of PubMed, Cochrane Library, Scopus, and Web of Science was employed from inception until April 2022 for randomized controlled trials (RCTs) in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, investigating the impact of MCT oils on com…

Non-demented1106 Human Movement and Sports Sciences1103 Clinical SciencesKetone BodiesKetosisMedium-chain triglyceridesNutritional ketosisMemoryGeriatricsVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Geriatri: 778HumansCognitive functionGeriatrics and GerontologyOilsTriglyceridesAgedRandomized Controlled Trials as TopicBMC geriatrics
researchProduct

La teneur en lipides du régime affecte les capacitésd'absorption intestinale et la triglycéridémie postprandiale: contribution du récepteur nucléaire…

2007

The dietary long chain fatty acid have crucial functions into the organism such as energysource, eicosanoïdes synthesis, gene regulation). The fat disposal is essential and depend onintestinal barrier. It is well known that intestinal fat absorption is efficient. However, we don'tif the high triglycerides bioavailability of gut is attributable to inborn properties or to acquiredproperties. To answer this question, mice were subjected to a high-fat diet (40%, w/w) during21 days. We have shown that high-fat induces : 1) intestinal LCFA uptake, 2) intestinalmitotic index which leads to an increase of intestinal relative mass, 3) expression of genesinvolved in fatty uptake (Fatty Acid Transport…

PPARβtriglyceridemiaintestinlipid-binding proteintriglycéridémie[OTHER] domain_otherproliférationsmall intestineabsorption
researchProduct

Carbohydrate quality changes and concurrent changes in cardiovascular risk factors: a longitudinal analysis in the PREDIMED-Plus randomized trial.

2020

[Background]: Overall quality of dietary carbohydrate intake rather than total carbohydrate intake may determine the risk of cardiovascular disease (CVD).

PREDIMED-Plus carbohydrate carbohydrate quality index cardiovascular disease fiber glycemic index obesity randomized controlled trialsMaleobesity030309 nutrition & dieteticsMedicine (miscellaneous)030204 cardiovascular system & hematologyOverweightchemistry.chemical_compound0302 clinical medicinecardiovascular diseaseRisk FactorsSurveys and QuestionnairesGlycemic indexLongitudinal StudiesProspective Studies2. Zero hunger0303 health sciencesNutrition and DieteticsMiddle AgedCardiovascular disease3. Good healthGlycemic indexCardiovascular Diseasesrandomized controlled trialsRandomized controlled trialsFemalemedicine.symptomfibermedicine.medical_specialtyWaistCarbohydrates03 medical and health sciencesInternal medicinemedicineDietary CarbohydratesHumansFiberObesityAgedCarbohydrate quality indexTriglyceridebusiness.industryPREDIMED-PlusOverweightmedicine.diseaseObesityDietBlood pressurechemistrycarbohydratecarbohydrate quality indexglycemic indexGlycated hemoglobinMetabolic syndromebusinessEnergy Intake
researchProduct

Emerging approaches for the treatment of hypertriglyceridemia.

2013

Hypertriglyceridemia is frequent in diabetic and obese subjects, who are at increased risk for cardiovascular diseases (CVD). Increased triglycerides (TG) are a hallmark of atherogenic dyslipidemia, representing a marker of atherogenic small dense low-density lipoproteins (sdlDL). Importantly, non-fasting/postprandial TG measurements tend to be emphasized in clinical practice for the prediction of CVD, and TG-lowering agents (primarily fibrates) have a beneficial effect on atherogenic dyslipidemia, reducing TG-rich particles and ultimately lowering the production of sdlDL. The combination of omega-3 fatty acids and statins is also recommended, and widely used in clinical practice for subjec…

PharmacologyHypertriglyceridemiamedicine.medical_specialtyAtherogenic dyslipidemiabusiness.industryHypertriglyceridemiaGeneral Medicinemedicine.diseaseBioinformaticsFish consumptionClinical PracticeEndocrinologyIncreased riskPostprandialInternal medicinecardiovascular diseases triglycerides hypertriglyceridemia triglyceride-lowering agentsmedicineIncreased triglyceridesHumansPharmacology (medical)Obese subjectsbusinessLife StyleHypolipidemic AgentsExpert opinion on pharmacotherapy
researchProduct

Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIb hyperlipoproteinemia

1994

Abstract A randomized, double-blind, parallel-group study of pravastatin versus placebo was carried out for 24 weeks in 20 patients with type IIb primary hyperlipoproteinemia. Total cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, blood glucose, apolipoproteins (apo) A1 and B, and lipoprotein (a) (Lp[a]) levels were determined. A venous occlusion test was also performed in all patients. Pre- and postvenous occlusion tests were determined: tissue plasminogen activator antigen (t-PA[Ag]), plasminogen activator inhibitor (PAI) activity, factor VII, fibrinogen, plasminogen, and hematocrit. Compared with placebo, pravastatin signi…

Pharmacologymedicine.medical_specialtyApolipoprotein BbiologyTriglyceridebusiness.industryCholesterolmedicine.medical_treatmentnutritional and metabolic diseasesFibrinogenchemistry.chemical_compoundEndocrinologychemistryInternal medicineFibrinolysismedicinebiology.proteinlipids (amino acids peptides and proteins)Pharmacology (medical)businessPlasminogen activatorPravastatinmedicine.drugLipoproteinCurrent Therapeutic Research
researchProduct

Effects of gemfibrozil in hyperlipidemic patients with or without diabetes

1993

Abstract Four hundred sixty-one hyperlipidemic men and women, aged 23 to 73 years, with (n = 200) or without (n = 261) non-insulin-dependent diabetes mellitus were included in a study designed to evaluate the efficacy and tolerability of 1,200 mg of gemfibrozil given once daily for 24 weeks. All lipid values improved significantly in both diabetic and nondiabetic patients during treatment. The number of patients with the atherogenic predictor ratio of low-density:high-density lipoprotein cholesterol (HDL-C:LDL-C) >5 decreased by 95% in both patient groups. The number of patients in the highest-risk subgroup with the combination risk factors of LDL-C:HDL-C >5 and triglyceride levels >200 mg/…

Pharmacologymedicine.medical_specialtyChemotherapyTriglyceridebusiness.industrymedicine.medical_treatmentmedicine.diseaseBody weightGastroenterologychemistry.chemical_compoundEndocrinologyBlood pressureTolerabilitychemistryInternal medicineDiabetes mellitusMedicineGemfibrozilPharmacology (medical)Once dailybusinessmedicine.drugCurrent Therapeutic Research
researchProduct

Effect of gemfibrozil treatment on fibrinolysis system in patients with hypertriglyceridemia

1992

Abstract The effect of gemfibrozil on lipidic, coagulative, and fibrinolytic pattern was studied in 20 patients with primary type IV hyperlipoproteinemia. After a 4-week stabilization period during which administration of lipid-lowering drugs was stopped and an isocaloric diet (20% protein, 30% fat, and 50% carbohydrates) was prescribed, 20 patients (12 men and 8 women; mean age, 38 ± 4 years; body mass index, 23.4 ± 1.5) suffering from primary hypertriglyceridemia were included in this study and treated for a 12-week period with gemfibrozil (600 mg BID). Every 4 weeks the following parameters were checked: glycemia, triglycerides, total cholesterol, high density lipoprotein-cholesterol, to…

Pharmacologymedicine.medical_specialtyFactor VIIbusiness.industrymedicine.medical_treatmentHypertriglyceridemiaAntithrombinmedicine.diseaseFibrinogenchemistry.chemical_compoundEndocrinologychemistryHemostasisInternal medicineFibrinolysismedicineGemfibrozillipids (amino acids peptides and proteins)Pharmacology (medical)businessPlasminogen activatormedicine.drugCurrent Therapeutic Research
researchProduct

Long-term effects of lercanidipine on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension

1999

Abstract The goal of this multicenter, randomized, double-masked, parallel- group study was to assess the effects of lercanidipine versus those of hydrochlorothiazide (HCTZ) on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension. After a 2-week washout period, 52 patients (age range, 18 to 70 years) were randomly allocated to receive lercanidipine 10 mg (n = 26) or HCTZ 12.5 mg (n = 26) once a day for 24 weeks. In nonresponding patients, the dose was increased to 20 or 30 mg of lercanidipine once a day and to 25 or 37.5 mg of HCTZ once a day, after 4 and 8 weeks, respectively. To assess long-term effects, patients receiving lercanidipine enter…

Pharmacologymedicine.medical_specialtyTriglyceridebusiness.industryLercanidipinemedicine.medical_treatmentUrologyEssential hypertensionmedicine.diseasechemistry.chemical_compoundHydrochlorothiazideEndocrinologychemistryInternal medicineHeart ratemedicinePharmacology (medical)DiureticbusinessThiazidemedicine.drugLipoproteinCurrent Therapeutic Research
researchProduct